RxDoctor Payments Data

Belma Maruflu, DDS

Maxillofacial Surgery · Tucson, AZNPI 1144306853

Payments from drug & device makers

$228in general payments, 2019–2025

Across 13 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$179
  • Lilly USA, LLC$34
  • Pfizer$15

What the payments were for

  • Food & beverage$228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis10$179
Lilly USA, LLC2$34
Pfizer1$15

How this compares

Too few maxillofacial surgery providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$339,936
Medicare patients
333
Services billed
3,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Baclofen209$2,346
Gabapentin18$261
Cyclobenzaprine Hcl17$140
Methylprednisolone17$123
Meloxicam62$109
Naproxen24$106

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →